By Doug Macron

Calando Pharmaceuticals could soon find a partner for its siRNA-based cancer drug CALAA-01 thanks to publication of positive data from an ongoing phase I trial of the drug, the head of parent firm Arrowhead Research said last week.

And although it will remain focused solely on CALAA-01 in the near term, Arrowhead is considering initiating new drug-development programs, CEO Christopher Anzalone said during the company's fiscal second-quarter earnings call.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Gene drives might run into biological resistance, the Economist reports.

Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.

Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.

In Science this week: full CRISPR locus integration complex structure, and more.